Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

描述(由申请人提供)：一种名为选择性细胞遗传学装置(SCD)的体外装置已经被制造出来，该装置可以隔离激活白细胞并抑制其释放炎症蛋白和细胞因子。白细胞是许多临床炎症性疾病发生和发展的主要因素，包括全身炎症反应综合征(SIRS)、脓毒症和急性呼吸窘迫综合征(ARDS)。目前正在研究大量的治疗方法，以限制炎症部位白细胞的激活和组织积聚，以最大限度地减少组织破坏和疾病进展。这项研究计划将在一种成熟的感染性休克、SIRS和早期ARDS的猪模型上评估这种SCD。治疗组和假治疗组将比较各种心血管参数、全身细胞因子水平以及肺部炎症与支气管肺泡灌洗(BAL)参数和死亡时间的关系。还将评估膜表面积和简化回路系统对正在进行的多器官功能障碍和炎症过程的影响。这一建议可能提出了一种改变全身炎症反应的方法，并可能导致一种新的脓毒症、SIRS和ARDS的治疗方法。

DESCRIPTION (provided by applicant): An extracorporeal device, named selective cytopheretic device (SCD), has been fabricated that sequesters activated leukocytes and inhibits their release of inflammatory proteins and cytokines. Leukocytes are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome (SIRS), sepsis and acute respiratory distress syndrome (ARDS). A large number of therapeutic approaches are under investigation to limit the activation and tissue accumulation of leukocytes at sites of inflammation in order to minimize tissue destruction and disease progression. This research proposal will evaluate this SCD on a well-developed porcine model of septic shock, SIRS and early ARDS. Various cardiovascular parameters, systemic cytokine levels, and pulmonary inflammation with bronchoalveolar lavage (BAL) parameters and time to death will be compared between treatment and sham treatment groups. The effects of membrane surface area and efficacy of a simplified circuit system on the ongoing multiorgan dysfunction and inflammatory processes will also be assessed. This proposal may suggest a manner of altering the systemic inflammatory response and may lead to a new therapeutic approach to sepsis, SIRS and ARDS.